Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: A randomized crossover study
| Autor: | A. Hamid Boulares, Samuel C. Okpechi, Judd E. Shellito, Matthew R. Lammi, Connie Romaine, John B. Zamjahn, Hahn H. Luu, Bennett P. deBoisblanc, Jessica L. Johnson, Mohamed A. Ghonim, Andy Pellett, Johnny D'Aquin, Kusma Pyakurel |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Male Placebo Article Pulmonary Disease Chronic Obstructive Oxygen Consumption Double-Blind Method Administration Inhalation medicine Humans Lung volumes Iloprost Dynamic hyperinflation Exercise Aged Inflammation COPD Cross-Over Studies business.industry Total Lung Capacity VO2 max respiratory system Middle Aged medicine.disease Crossover study Pulmonary hypertension Oxidative Stress Anesthesia Exercise Test Female business Lung Volume Measurements medicine.drug |
| Zdroj: | Respir Med |
| ISSN: | 1532-3064 |
| Popis: | Background and objective We tested whether the prostacyclin analog inhaled iloprost modulates dead space, dynamic hyperinflation (DH), and systemic inflammation/oxidative stress during maximal exercise in subjects with chronic obstructive pulmonary disease (COPD) who were not selected based on pulmonary hypertension (PH). Methods Twenty-four COPD patients with moderate-severe obstruction (age 59 ± 7 years, FEV1 53 ± 13% predicted) participated in a randomized, double-blind, placebo-controlled crossover trial. Each subject received a single nebulized dose of 5.0 μg iloprost or placebo on non-consecutive days followed by maximal cardiopulmonary exercise tests. The primary outcome was DH quantified by end-expiratory lung volume/total lung capacity ratio (EELV/TLC) at metabolic isotime. Results Inhaled iloprost was well-tolerated and reduced submaximal alveolar dead-space fraction but did not significantly reduce DH (0.70 ± 0.09 vs 0.69 ± 0.07 following placebo and iloprost, respectively, p = 0.38). Maximal exercise time (9.1 ± 2.3 vs 9.3 ± 2.2 min, p = 0.31) and peak oxygen uptake (17.4 ± 6.3 vs 17.9 ± 6.9 mL/kg/min, p = 0.30) were not significantly different following placebo versus iloprost. Conclusions A single dose of inhaled iloprost was safe and reduced alveolar dead space fraction; however, it was not efficacious in modulating DH or improving exercise capacity in COPD patients who were not selected for the presence of PH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect